Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
In vitro inhibition of recombinant ligand-gated ion channels by high concentrations of milnacipran.
Ueta K
,
Suzuki T
,
Uchida I
,
Mashimo T
.
???displayArticle.abstract???
RATIONALE: Tricyclic antidepressants are known to inhibit various ligand-gated ion-channel (LGIC) receptors, and some of their clinical features may be associated with this activity. The effects of milnacipran, a selective inhibitor of the reuptake of serotonin and noradrenaline, on LGIC receptors have not yet been investigated on such ion-channel receptors.
OBJECTIVES: To determine the in vitro effect of milnacipran on four recombinant LGIC receptors, nicotinic acetylcholine, N-methyl-D-aspartate, gamma-amino butyric acid (GABA) and 5-hydroxytryptamine3A receptors.
METHODS: Receptors were expressed in Xenopus oocytes and LGIC activity measured using a two-voltage clamp technique.
RESULTS: There was no interaction at the GABA receptor. The results at the other LGIC receptors showed that they could be inhibited by high concentrations of milnacipran.
CONCLUSIONS: At high concentrations, milnacipran can inhibit certain LGICs. It is, however, unlikely that these interactions have any clinical consequence under normal therapeutic conditions, since the concentrations required are considerably higher than those achieved in plasma of treated patients.
Asahi,
Involvement of GABAergic systems in manifestation of pharmacological activity of desipramine.
2001, Pubmed
Asahi,
Involvement of GABAergic systems in manifestation of pharmacological activity of desipramine.
2001,
Pubmed
Briley,
Fibromyalgia syndrome: an overview of potential drug targets.
2003,
Pubmed
Briley,
New hope in the treatment of painful symptoms in depression.
2003,
Pubmed
Decker,
The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control.
2001,
Pubmed
Fan,
Effects of antidepressants on the inward current mediated by 5-HT3 receptors in rat nodose ganglion neurones.
1994,
Pubmed
Favale,
Anticonvulsant effect of fluoxetine in humans.
1995,
Pubmed
Fryer,
Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function.
1999,
Pubmed
Gumilar,
Molecular mechanisms of inhibition of nicotinic acetylcholine receptors by tricyclic antidepressants.
2003,
Pubmed
Hewitt,
N-methyl-D-aspartate- enhanced analgesia.
2003,
Pubmed
Izaguirre,
Tricyclic antidepressants block cholinergic nicotinic receptors and ATP secretion in bovine chromaffin cells.
1997,
Pubmed
Kranzler,
The psychopharmacology of fibromyalgia: a drug development perspective.
2002,
Pubmed
Lancaster,
Desmethylimipramine potentiates NMDA responses in a mouse cortical slice preparation.
1991,
Pubmed
Lloyd,
The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents.
1998,
Pubmed
López-Valdés,
Antagonism of nicotinic acetylcholine receptors by inhibitors of monoamine uptake.
2001,
Pubmed
,
Xenbase
López-Valdés,
Effects of clomipramine on neuronal nicotinic acetylcholine receptors.
2002,
Pubmed
,
Xenbase
Malatynska,
Antidepressants and seizure-interactions at the GABA-receptor chloride-ionophore complex.
1988,
Pubmed
Mochizuki,
Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats.
2002,
Pubmed
Moret,
Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug.
1985,
Pubmed
Pacher,
Current trends in the development of new antidepressants.
2001,
Pubmed
Papadopoulos,
Treatment of fibromyalgia with tropisetron, a 5HT3 serotonin antagonist: a pilot study.
2000,
Pubmed
Petrenko,
The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review.
2003,
Pubmed
Preskorn,
Plasma levels of imipramine and adverse effects in children.
1983,
Pubmed
Puech,
Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.
1997,
Pubmed
Puozzo,
Pharmacokinetics of milnacipran in comparison with other antidepressants.
1996,
Pubmed
Rana,
Inhibition of neuronal nicotinic acetylcholine receptors by imipramine and desipramine.
1993,
Pubmed
Robinson,
Fluoxetine increases GABA(A) receptor activity through a novel modulatory site.
2003,
Pubmed
Shuto,
(+/-)-(Z)-2-(aminomethyl)-1-phenylcyclopropanecarboxamide derivatives as a new prototype of NMDA receptor antagonists.
1995,
Pubmed
Shuto,
Synthesis and biological activity of conformationally restricted analogues of milnacipran: (1S, 2R)-1-phenyl-2-[(R)-1-amino-2-propynyl]-N,N- diethylcyclopropanecarboxamide is a novel class of NMDA receptor channel blocker.
1998,
Pubmed
,
Xenbase
Stahl,
Does depression hurt?
2002,
Pubmed
Stenger,
Psychopharmacology of midalcipran, 1-phenyl-1-diethyl-amino-carbonyl-2-aminomethylcyclopropane hydrochloride (F 2207), a new potential antidepressant.
1987,
Pubmed
Sugimoto,
Evidence for the involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins.
2003,
Pubmed
,
Xenbase
Sugimoto,
Local anaesthetics have different mechanisms and sites of action at the recombinant N-methyl-D-aspartate (NMDA) receptors.
2003,
Pubmed
,
Xenbase
Tassonyi,
The role of nicotinic acetylcholine receptors in the mechanisms of anesthesia.
2002,
Pubmed
Watanabe,
Tricyclic antidepressants block NMDA receptor-mediated synaptic responses and induction of long-term potentiation in rat hippocampal slices.
1993,
Pubmed
White,
Inhibition of N-methyl-D-aspartate activated ion current by desmethylimipramine.
1990,
Pubmed
